Abbott (NYSE:ABT) reportedly won’t introduce its next-generation drug-eluting stent, the Xience Sierra, to the Indian market due to price caps there.
The everolimus-eluting coronary stent, which won CE Mark approval in the European Union this week, is designed to allow cardiologists to treat the complex lesions that make up roughly 70% of cases. It offers a thinner profile, increased flexibility, longer lengths and smaller diameters than previous stents.
Get the full story at our sister site, Drug Delivery Business News.